Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 3 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Tegoprazan noninferior to lansoprazole for gastric ulcers

09 Sep 2020

Two doses of the novel potassium‐competitive acid blocker tegoprazan show comparable healing effects on gastric ulcers as lansoprazole, while having a favourable safety profile, according to the results of a phase III trial.

A total of 306 gastric ulcer patients were randomized to treatment with tegoprazan 50 mg or 100 mg or lansoprazole 30 mg once daily for 4 or 8 weeks. Men comprised the majority of the population, and the average age of the patients was 54 years. Ulcers were commonly <10 mm, and most patients had a single ulcer.

There were 28 patients (9.2 percent) who withdrew from the trial because of voluntary withdrawal, inclusion/exclusion criteria violation, use of contraindicated drugs, adverse events (AEs), follow‐up loss, or investigator discretion.

In the per-protocol analysis, both doses of tegoprazan were noninferior to lansoprazole in terms of ulcer healing at 4 and 8 weeks. The cumulative proportion of patients with endoscopy-confirmed healed ulcers over the 8‐week treatment period were 100 percent with tegoprazan 50 mg, 97.85 percent with tegoprazan 100 mg, and 100 percent with lansoprazole 30 mg group. The corresponding healing rates at week 4 were 95.45 percent, 94.62 percent, and 92.94 percent.

The noninferiority of tegoprazan was confirmed in the full-analysis set. The respective healing rates were 94.8 percent, 95.0 percent, and 95.7 percent at week 8, and 90.6 percent, 91.9 percent, and 89.2 percent at week 4.

There were no significant differences in the incidence of drug‐related treatment‐emergent adverse events across the three groups (9.80 with tegoprazan 50 mg, 13.73 percent with tegoprazan 100 mg group, and 12.00 percent with lansoprazole 30 mg). The increase in serum gastrin concentration was similar in tegoprazan‐treated and lansoprazole‐treated patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 3 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.